Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences
Trevi Therapeutics, a clinical-stage biopharmaceutical company developing Haduvio™ for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), announced its participation in upcoming commercial and investor conferences. The company's senior management will attend three events:
1. 3rd Chief Commercial Officer Summit in Philadelphia, PA (October 23-24, 2024), where Farrell Simon will present on Commercial's Role in Clinical Trial Recruitment.
2. BIO-Europe in Stockholm, Sweden (November 4-6, 2024), with Farrell Simon representing Trevi.
3. Stifel 2024 Healthcare Conference in New York, NY (November 18-19, 2024), featuring a corporate presentation by Jennifer Good and Lisa Delfini.
These events provide opportunities for Trevi to showcase its progress in developing Haduvio™ and engage with industry professionals and investors.
Trevi Therapeutics, un'azienda biofarmaceutica in fase clinica che sviluppa Haduvio™ per la tosse cronica nella fibrosi polmonare idiopatica (IPF) e per la tosse cronica refrattaria (RCC), ha annunciato la sua partecipazione a prossimi eventi commerciali e conferenze per investitori. Il senior management dell'azienda parteciperà a tre eventi:
1. 3rd Chief Commercial Officer Summit a Philadelphia, PA (23-24 ottobre 2024), dove Farrell Simon presenterà il ruolo commerciale nella reclutamento per studi clinici.
2. BIO-Europe a Stoccolma, Svezia (4-6 novembre 2024), con Farrell Simon che rappresenta Trevi.
3. Stifel 2024 Healthcare Conference a New York, NY (18-19 novembre 2024), con una presentazione aziendale di Jennifer Good e Lisa Delfini.
Questi eventi offrono opportunità a Trevi per mostrare i suoi progressi nello sviluppo di Haduvio™ e interagire con professionisti del settore e investitori.
Trevi Therapeutics, una empresa biofarmacéutica en etapa clínica que desarrolla Haduvio™ para la tosse crónica en fibrosis pulmonar idiopática (IPF) y tos crónica refractaria (RCC), anunció su participación en próximas conferencias comerciales y para inversionistas. La alta dirección de la empresa asistirá a tres eventos:
1. 3rd Chief Commercial Officer Summit en Filadelfia, PA (23-24 de octubre de 2024), donde Farrell Simon presentará sobre el papel comercial en el reclutamiento de ensayos clínicos.
2. BIO-Europe en Estocolmo, Suecia (4-6 de noviembre de 2024), con Farrell Simon representando a Trevi.
3. Stifel 2024 Healthcare Conference en Nueva York, NY (18-19 de noviembre de 2024), con una presentación corporativa de Jennifer Good y Lisa Delfini.
Estos eventos brindan oportunidades para que Trevi muestre su progreso en el desarrollo de Haduvio™ y se relacione con profesionales de la industria e inversionistas.
Trevi Therapeutics는 특발성 폐섬유증(IPF) 및 난치성 만성 기침(RCC)을 위한 만성 기침 치료제로 Haduvio™를 개발 중인 임상 단계의 바이오 제약 회사로, 다가오는 상업 및 투자자 회의에 참여할 것이라고 발표했습니다. 회사의 고위 경영진은 세 가지 행사에 참석할 예정입니다:
1. 3rd Chief Commercial Officer Summit 필라델피아, PA (2024년 10월 23-24일)에서 Farrell Simon이 임상 시험 모집에서 상업의 역할에 대해 발표합니다.
2. BIO-Europe 스톡홀름, 스웨덴 (2024년 11월 4-6일)에서 Farrell Simon이 Trevi를 대신합니다.
3. Stifel 2024 Healthcare Conference 뉴욕, NY (2024년 11월 18-19일)에서 Jennifer Good와 Lisa Delfini가 기업 발표를 진행합니다.
이러한 이벤트는 Trevi가 Haduvio™ 개발의 진행 상황을 선보이고 산업 전문가 및 투자자들과 교류할 수 있는 기회를 제공합니다.
Trevi Therapeutics, une entreprise biopharmaceutique en phase clinique développant Haduvio™ pour la toux chronique dans la fibrose pulmonaire idiopathique (IPF) et la toux chronique réfractaire (RCC), a annoncé sa participation à des conférences commerciales et pour investisseurs à venir. La direction senior de l'entreprise assistera à trois événements :
1. 3rd Chief Commercial Officer Summit à Philadelphie, PA (23-24 octobre 2024), où Farrell Simon présentera le rôle commercial dans le recrutement d'essais cliniques.
2. BIO-Europe à Stockholm, Suède (4-6 novembre 2024), avec Farrell Simon représentant Trevi.
3. Stifel 2024 Healthcare Conference à New York, NY (18-19 novembre 2024), avec une présentation d'entreprise par Jennifer Good et Lisa Delfini.
Ces événements offrent à Trevi des opportunités de présenter ses progrès dans le développement de Haduvio™ et d'interagir avec des professionnels de l'industrie et des investisseurs.
Trevi Therapeutics, ein biopharmazeutisches Unternehmen in der klinischen Phase, das Haduvio™ zur Behandlung von chronischem Husten bei idiopathischer Lungenfibrose (IPF) und refraktärem chronischen Husten (RCC) entwickelt, hat seine Teilnahme an bevorstehenden Handels- und Investorenkonferenzen angekündigt. Das Senior Management des Unternehmens wird an drei Veranstaltungen teilnehmen:
1. 3rd Chief Commercial Officer Summit in Philadelphia, PA (23.-24. Oktober 2024), wo Farrell Simon über die Rolle des Handels bei der Rekrutierung von klinischen Studien sprechen wird.
2. BIO-Europe in Stockholm, Schweden (4.-6. November 2024), mit Farrell Simon, der Trevi vertreten wird.
3. Stifel 2024 Healthcare Conference in New York, NY (18.-19. November 2024), mit einer Unternehmenspräsentation von Jennifer Good und Lisa Delfini.
Diese Veranstaltungen bieten Trevi die Möglichkeit, seinen Fortschritt bei der Entwicklung von Haduvio™ zu präsentieren und mit Fachleuten und Investoren aus der Branche zu interagieren.
- None.
- None.
3rd Chief Commercial Officer Summit
October 23-24, 2024,
Oral Presentation: Commercial's Role in Clinical Trial Recruitment
Presentation: October 23, 1:30pm EDT
Trevi Representative: Farrell Simon, Chief Commercial Officer
Register here
BIO-Europe
November 4-6, 2024,
Trevi Representative: Farrell Simon, Chief Commercial Officer
Register here
Stifel 2024 Healthcare Conference
November 18-19, 2024,
Corporate Presentation: November 18, 11:30am EDT
Trevi Representatives: Jennifer Good, President and CEO, Lisa Delfini, Chief Financial Officer
Register here to watch the live presentation
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio is an extended-release (ER) dual ĸ-opioid receptor agonist and µ-opioid receptor antagonist that works both centrally in the brain as well as peripherally in the lungs and has the potential for a synergistic antitussive effect to treat chronic cough. Parenteral nalbuphine is not scheduled by the
The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal benefit to patients. Chronic cough affects up to
Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
Katie Barrett
Trevi Therapeutics, Inc.
203-304-2499
k.barrett@trevitherapeutics.com
Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-upcoming-commercial-and-investor-conferences-302275584.html
SOURCE Trevi Therapeutics, Inc.
FAQ
What conferences will Trevi Therapeutics (TRVI) attend in October and November 2024?
Who will represent Trevi Therapeutics (TRVI) at the upcoming conferences?
What is Trevi Therapeutics (TRVI) developing Haduvio™ for?
When and where will Trevi Therapeutics (TRVI) present at the Stifel 2024 Healthcare Conference?
